Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 19/20 | 0.55 |
| ▸ | MMP13 | P45452 | 17/20 | 0.55 |
| ▸ | MMP2 | P08253 | 5/20 | 0.53 |
| ▸ | MMP1 | P03956 | 12/20 | 0.52 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3944455 | 0.87 | ADAM17 (0.57) | ADAM17MMP13MMP2MMP1MMP9 | |
| SCHEMBL3944450 | 0.87 | ADAM17 (0.57) | ADAM17MMP13MMP2MMP1MMP9 | |
| SCHEMBL3947785 | 0.87 | ADAM17 (0.57) | ADAM17MMP13MMP2MMP1MMP9 | |
| SCHEMBL3937331 | 0.84 | ADAM17 (0.57) | ADAM17MMP13MMP2MMP1MMP9 | |
| SCHEMBL3938831 | 0.79 | ADAM17 (0.59) | ADAM17MMP13MMP2MMP1MMP9 | |
| SCHEMBL3942784 | 0.79 | ADAM17 (0.59) | ADAM17MMP13MMP2MMP1MMP9 | |
| SCHEMBL3942787 | 0.79 | ADAM17 (0.59) | ADAM17MMP13MMP2MMP1MMP9 | |
| SCHEMBL3942789 | 0.79 | ADAM17 (0.59) | ADAM17MMP13MMP2MMP1MMP9 | |
| SCHEMBL4148426 | 0.77 | ADAM17 (0.59) | ADAM17MMP13MMP2MMP1MMP9 | |
| SCHEMBL7872276 | 0.76 | ADAM17 (0.53) | ADAM17MMP13MMP2MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147078-A1 | ACETYLENIC (BETA)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2000044711-A1 | ACETYLENIC $G(b)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | claimed |
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
| WO-2002083112-A2 | METHOD FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH HOLDINGS CORPORATION (US) | 2002-10-24 | — | — | WO | disclosed |
| US-6326516-B1 | RHEUMATIC DISEASES; SEPSIS; ANTIULCER AGENTS | AMERICAN CYANAMID COMPANY | 2001-12-04 | — | — | US | disclosed |
| EP-1147078-A1 | ACETYLENIC (BETA)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044711-A1 | ACETYLENIC $G(b)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | PKD1, PKD2, PCSK6 | ADAM17 9/4885MMP13 246/4885MMP2 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.